{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T07:19:15Z","timestamp":1789802355193,"version":"4.0.1"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.ejps.2020.105370","type":"journal-article","created":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T23:09:52Z","timestamp":1588720192000},"page":"105370","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Population pharmacokinetics of mycophenolic acid in adult kidney transplant patients under prednisone and tacrolimus regimen"],"prefix":"10.1016","volume":"150","author":[{"given":"Juan Eduardo","family":"Res\u00e9ndiz-Galv\u00e1n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Romano-Aguilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3962-8474","authenticated-orcid":false,"given":"Susanna Edith","family":"Medell\u00edn-Garibay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa del Carmen","family":"Mil\u00e1n-Segovia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perla del Carmen","family":"Ni\u00f1o-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helgi","family":"Jung-Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Alejandro","family":"Chevaile-Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4885-3745","authenticated-orcid":false,"given":"Silvia","family":"Romano-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2020.105370_bib0001","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.1097\/01.tp.0000186390.10150.66","article-title":"Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection","volume":"80","author":"Allison","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.ejps.2020.105370_bib0002","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/cpt1977222147","article-title":"Alteration of plasma albumin in relation to decreased drug binding in uremia","volume":"22","author":"Boobis","year":"1977","journal-title":"Clinical pharmacology and therapeutics"},{"key":"10.1016\/j.ejps.2020.105370_bib0003","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/FTD.0b013e3181c91fc4","article-title":"Mycophenolic acid predose concentrations and renal function in a mouse model for progressive renal fibrosis","volume":"32","author":"Brandhorst","year":"2010","journal-title":"Therapeutic drug monitoring"},{"key":"10.1016\/j.ejps.2020.105370_bib0004","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/j.1552-4604.1996.tb04207.x","article-title":"Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration","volume":"36","author":"Bullingham","year":"1996","journal-title":"Journal of clinical pharmacology"},{"key":"10.1016\/j.ejps.2020.105370_bib0005","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2165\/00003088-199834060-00002","article-title":"Clinical pharmacokinetics of mycophenolate mofetil","volume":"34","author":"Bullingham","year":"1998","journal-title":"Clinical pharmacokinetics"},{"key":"10.1016\/j.ejps.2020.105370_bib0006","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/FTD.0000000000000165","article-title":"Limited sampling strategy for predicting area under the concentration-time curve for mycophenolic Acid in Chinese adults receiving mycophenolate mofetil and tacrolimus early after renal transplantation","volume":"37","author":"Cai","year":"2015","journal-title":"Therapeutic drug monitoring"},{"key":"10.1016\/j.ejps.2020.105370_bib0007","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1016\/j.ejps.2020.105370_bib0008","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1365-2125.2005.02398.x","article-title":"Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling","volume":"60","author":"Cremers","year":"2005","journal-title":"British journal of clinical pharmacology"},{"key":"10.1016\/j.ejps.2020.105370_bib0009","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.transproceed.2012.10.030","article-title":"Influence of serum uric acid levels in response to the conversion from mycophenolate mofetil to mizoribine in kidney transplant recipients","volume":"45","author":"Ding","year":"2013","journal-title":"Transplantation proceedings"},{"key":"10.1016\/j.ejps.2020.105370_bib0010","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/FPC.0b013e32801430f8","article-title":"Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients","volume":"17","author":"Djebli","year":"2007","journal-title":"Pharmacogenetics and genomics"},{"key":"10.1016\/j.ejps.2020.105370_bib0011","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1177\/0091270003253624","article-title":"Model appropriateness and population pharmacokinetic modeling","volume":"43","author":"Ette","year":"2003","journal-title":"Journal of clinical pharmacology"},{"key":"10.1016\/j.ejps.2020.105370_bib0012","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1365-3083.1991.tb03746.x","article-title":"Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion","volume":"33","author":"Eugui","year":"1991","journal-title":"Scandinavian journal of immunology"},{"key":"10.1016\/j.ejps.2020.105370_bib0013","first-page":"29682","article-title":"Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans","volume":"270","author":"Fairbanks","year":"1995","journal-title":"Disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors. The Journal of biological chemistry"},{"key":"10.1016\/j.ejps.2020.105370_bib0014","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1124\/dmd.110.034249","article-title":"Involvement of carboxylesterase 1 and 2 in the hydrolysis of mycophenolate mofetil","volume":"38","author":"Fujiyama","year":"2010","journal-title":"Drug metabolism and disposition: the biological fate of chemicals"},{"key":"10.1016\/j.ejps.2020.105370_bib0015","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1097\/01.fpc.0000114754.08559.27","article-title":"Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver","volume":"14","author":"Girard","year":"2004","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.ejps.2020.105370_bib0016","first-page":"170","article-title":"Markers of renal function tests","volume":"2","author":"Gowda","year":"2010","journal-title":"North American journal of medical sciences"},{"key":"10.1016\/j.ejps.2020.105370_bib0017","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0009-9236(98)90058-3","article-title":"The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation","volume":"64","author":"Hale","year":"1998","journal-title":"Clinical pharmacology and therapeutics"},{"key":"10.1016\/j.ejps.2020.105370_bib0018","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s00228-014-1728-4","article-title":"Population pharmacogenetic pharmacokinetic modeling for flip-flop phenomenon of enteric-coated mycophenolate sodium in kidney transplant recipients","volume":"70","author":"Han","year":"2014","journal-title":"European journal of clinical pharmacology"},{"key":"10.1016\/j.ejps.2020.105370_bib0019","first-page":"134","article-title":"Gout and the regulation of purine biosynthesis","volume":"2","author":"Hershfield","year":"1976","journal-title":"Horizons in biochemistry and biophysics"},{"key":"10.1016\/j.ejps.2020.105370_bib0020","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1046\/j.1600-6143.2005.00779.x","article-title":"Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2","volume":"5","author":"Hesselink","year":"2005","journal-title":"American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons"},{"key":"10.1016\/j.ejps.2020.105370_bib0021","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.clpt.2005.05.011","article-title":"Transporters and drug therapy: implications for drug disposition and disease","volume":"78","author":"Ho","year":"2005","journal-title":"Clinical pharmacology and therapeutics"},{"key":"10.1016\/j.ejps.2020.105370_bib0022","doi-asserted-by":"crossref","DOI":"10.3390\/cells8060601","article-title":"Induction of Fibrosis and Autophagy in Kidney Cells by Vinyl Chloride","volume":"8","author":"Hsu","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.ejps.2020.105370_bib0023","doi-asserted-by":"crossref","first-page":"E523","DOI":"10.1208\/aapsj070353","article-title":"A new equivalence based metric for predictive check to qualify mixed-effects models","volume":"7","author":"Jadhav","year":"2005","journal-title":"The AAPS journal"},{"key":"10.1016\/j.ejps.2020.105370_bib0024","doi-asserted-by":"crossref","first-page":"184","DOI":"10.2215\/CJN.02860806","article-title":"Therapeutic monitoring of mycophenolate mofetil","volume":"2","author":"Jeong","year":"2007","journal-title":"Clinical journal of the American Society of Nephrology: CJASN"},{"key":"10.1016\/j.ejps.2020.105370_bib0025","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1007\/s00228-008-0501-y","article-title":"Pharmacogenetic effect of the UGT polymorphisms on mycophenolate is modified by calcineurin inhibitors","volume":"64","author":"Johnson","year":"2008","journal-title":"European journal of clinical pharmacology"},{"key":"10.1016\/j.ejps.2020.105370_bib0026","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0169-2607(98)00067-4","article-title":"Xpose\u2013an S-PLUS based population pharmacokinetic\/pharmacodynamic model building aid for NONMEM","volume":"58","author":"Jonsson","year":"1999","journal-title":"Computer methods and programs in biomedicine"},{"key":"10.1016\/j.ejps.2020.105370_bib0027","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.2215\/CJN.01230211","article-title":"Monitoring and managing graft health in the kidney transplant recipient","volume":"6","author":"Josephson","year":"2011","journal-title":"Clinical journal of the American Society of Nephrology: CJASN"},{"key":"10.1016\/j.ejps.2020.105370_bib0028","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1177\/00912709922008353","article-title":"The effect of renal insufficiency on mycophenolic acid protein binding","volume":"39","author":"Kaplan","year":"1999","journal-title":"Journal of clinical pharmacology"},{"key":"10.1016\/j.ejps.2020.105370_bib0029","first-page":"e50","article-title":"Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose","volume":"2","author":"Keizer","year":"2013","journal-title":"CPT: pharmacometrics & systems pharmacology"},{"key":"10.1016\/j.ejps.2020.105370_bib0030","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/ndt\/gfr616","article-title":"Albumin-binding capacity (ABiC) is reduced in patients with chronic kidney disease along with an accumulation of protein-bound uraemic toxins","volume":"27","author":"Klammt","year":"2012","journal-title":"Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association"},{"key":"10.1016\/j.ejps.2020.105370_bib0031","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2215\/CJN.07111009","article-title":"Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation","volume":"5","author":"Kuypers","year":"2010","journal-title":"Clinical journal of the American Society of Nephrology: CJASN"},{"key":"10.1016\/j.ejps.2020.105370_bib0032","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.clpt.2005.06.007","article-title":"The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients","volume":"78","author":"Kuypers","year":"2005","journal-title":"Clinical pharmacology and therapeutics"},{"key":"10.1016\/j.ejps.2020.105370_bib0033","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/FPC.0000000000000010","article-title":"PharmGKB summary: mycophenolic acid pathway","volume":"24","author":"Lamba","year":"2014","journal-title":"Pharmacogenetics and genomics"},{"key":"10.1016\/j.ejps.2020.105370_bib0034","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.trre.2011.01.002","article-title":"Therapeutic drug monitoring of mycophenolates in kidney transplantation: report of The Transplantation Society consensus meeting","volume":"25","author":"Le Meur","year":"2011","journal-title":"Transplantation reviews"},{"key":"10.1016\/j.ejps.2020.105370_bib0035","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1023\/A:1015828802490","article-title":"Bioavailability improvement of mycophenolic acid through amino ester derivatization","volume":"7","author":"Lee","year":"1990","journal-title":"Pharmaceutical research"},{"key":"10.1016\/j.ejps.2020.105370_bib0036","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","article-title":"PsN-Toolkit\u2013a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM","volume":"79","author":"Lindbom","year":"2005","journal-title":"Computer methods and programs in biomedicine"},{"key":"10.1016\/j.ejps.2020.105370_bib0037","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/00007691-200002000-00002","article-title":"Identification of uridine diphosphate glucuronosyltransferases involved in the metabolism and clearance of mycophenolic acid","volume":"22","author":"Mackenzie","year":"2000","journal-title":"Therapeutic drug monitoring"},{"key":"10.1016\/j.ejps.2020.105370_bib0038","first-page":"547","article-title":"Impact of UGT1A9 Polymorphism on Mycophenolic Acid Pharmacokinetic Parameters in Stable Renal Transplant Patients","volume":"12","author":"Mazidi","year":"2013","journal-title":"Iranian journal of pharmaceutical research: IJPR"},{"key":"10.1016\/j.ejps.2020.105370_bib0039","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s00228-007-0380-7","article-title":"Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients","volume":"63","author":"Miura","year":"2007","journal-title":"European journal of clinical pharmacology"},{"key":"10.1016\/j.ejps.2020.105370_bib0040","first-page":"e38","article-title":"Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods","volume":"2","author":"Mould","year":"2013","journal-title":"CPT: pharmacometrics & systems pharmacology"},{"key":"10.1016\/j.ejps.2020.105370_bib0041","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1097\/01.tp.0000235533.29300.e7","article-title":"Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients","volume":"82","author":"Naesens","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.ejps.2020.105370_bib0042","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/j.1552-4604.1996.tb04209.x","article-title":"Pharmacokinetics of oral mycophenolate mofetil in volunteer subjects with varying degrees of hepatic oxidative impairment","volume":"36","author":"Parker","year":"1996","journal-title":"Journal of clinical pharmacology"},{"key":"10.1016\/j.ejps.2020.105370_bib0043","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/01.ftd.0000159784.25872.f6","article-title":"Population pharmacokinetics of mycophenolic acid in kidney transplant pediatric and adolescent patients","volume":"27","author":"Payen","year":"2005","journal-title":"Therapeutic drug monitoring"},{"key":"10.1016\/j.ejps.2020.105370_bib0044","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1124\/dmd.104.001651","article-title":"Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism","volume":"33","author":"Picard","year":"2005","journal-title":"Drug metabolism and disposition: the biological fate of chemicals"},{"key":"10.1016\/j.ejps.2020.105370_bib0045","doi-asserted-by":"crossref","first-page":"4986","DOI":"10.4049\/jimmunol.170.10.4986","article-title":"Differential control of cell cycle, proliferation, and survival of primary T lymphocytes by purine and pyrimidine nucleotides","volume":"170","author":"Quemeneur","year":"2003","journal-title":"Journal of immunology"},{"key":"10.1016\/j.ejps.2020.105370_bib0046","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1097\/00007691-199512000-00023","article-title":"Mechanism of action of mycophenolate mofetil","volume":"17","author":"Ransom","year":"1995","journal-title":"Therapeutic drug monitoring"},{"key":"10.1016\/j.ejps.2020.105370_bib0047","doi-asserted-by":"crossref","first-page":"e4681","DOI":"10.1002\/bmc.4681","article-title":"Determination of mycophenolic acid in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry and its pharmacokinetic application in kidney transplant patients","author":"Resendiz-Galvan","year":"2019","journal-title":"Biomed Chromatogr"},{"key":"10.1016\/j.ejps.2020.105370_bib0048","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/FTD.0b013e318255cc15","article-title":"Limited-sampling strategy for mycophenolic acid in renal transplant recipients reciving enteric-coated mycophenolate sodium and tacrolimus","volume":"34","author":"Sanchez Fructuoso","year":"2012","journal-title":"Therapeutic drug monitoring"},{"key":"10.1016\/j.ejps.2020.105370_bib0049","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1208\/s12248-009-9133-0","article-title":"Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions","volume":"11","author":"Savic","year":"2009","journal-title":"The AAPS journal"},{"key":"10.1016\/j.ejps.2020.105370_bib0050","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s12882-019-1306-1","article-title":"Blood urea nitrogen is independently associated with renal outcomes in Japanese patients with stage 3-5 chronic kidney disease: a prospective observational study","volume":"20","author":"Seki","year":"2019","journal-title":"BMC nephrology"},{"key":"10.1016\/j.ejps.2020.105370_bib0051","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.2215\/CJN.03861106","article-title":"Therapeutic drug monitoring of mycophenolic acid","volume":"2","author":"Shaw","year":"2007","journal-title":"Clinical journal of the American Society of Nephrology: CJASN"},{"key":"10.1016\/j.ejps.2020.105370_bib0052","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1034\/j.1600-6143.2003.00079.x","article-title":"Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies","volume":"3","author":"Shaw","year":"2003","journal-title":"American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons"},{"key":"10.1016\/j.ejps.2020.105370_bib0053","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/11536640-000000000-00000","article-title":"The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease","volume":"50","author":"Sherwin","year":"2011","journal-title":"Clinical pharmacokinetics"},{"key":"10.1016\/j.ejps.2020.105370_bib0054","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S0041-1345(00)02424-6","article-title":"The acyl glucuronide metabolite of mycophenolic acid inhibits the proliferation of human mononuclear leukocytes","volume":"33","author":"Shipkova","year":"2001","journal-title":"Transplantation proceedings"},{"key":"10.1016\/j.ejps.2020.105370_bib0055","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2165\/00003088-200544100-00006","article-title":"Population pharmacokinetics of mycophenolic acid in renal transplant recipients","volume":"44","author":"van Hest","year":"2005","journal-title":"Clinical pharmacokinetics"},{"key":"10.1016\/j.ejps.2020.105370_bib0056","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/clpt.2009.83","article-title":"UGT1A9 -275T>A\/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF\/tacrolimus-treated kidney transplant patients","volume":"86","author":"van Schaik","year":"2009","journal-title":"Clinical pharmacology and therapeutics"},{"key":"10.1016\/j.ejps.2020.105370_bib0057","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1124\/dmd.105.006122","article-title":"Role of Mrp2 in the hepatic disposition of mycophenolic acid and its glucuronide metabolites: effect of cyclosporine","volume":"34","author":"Westley","year":"2006","journal-title":"Drug metabolism and disposition: the biological fate of chemicals"},{"key":"10.1016\/j.ejps.2020.105370_bib0058","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1208\/s12248-012-9407-9","article-title":"Shrinkage in nonlinear mixed-effects population models: quantification, influencing factors, and impact","volume":"14","author":"Xu","year":"2012","journal-title":"The AAPS journal"},{"key":"10.1016\/j.ejps.2020.105370_bib0059","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1177\/0091270009332813","article-title":"Mechanism-based enterohepatic circulation model of mycophenolic acid and its glucuronide metabolite: assessment of impact of cyclosporine dose in Asian renal transplant patients","volume":"49","author":"Yau","year":"2009","journal-title":"Journal of clinical pharmacology"},{"key":"10.1016\/j.ejps.2020.105370_bib0060","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1038\/aps.2017.115","article-title":"Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in Chinese adult renal transplant recipients","volume":"38","author":"Yu","year":"2017","journal-title":"Acta pharmacologica Sinica"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098720301597?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098720301597?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T11:52:27Z","timestamp":1760529147000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098720301597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":60,"alternative-id":["S0928098720301597"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2020.105370","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Population pharmacokinetics of mycophenolic acid in adult kidney transplant patients under prednisone and tacrolimus regimen","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2020.105370","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105370"}}